Cloxasaph-250

Cloxasaph-250 Uses, Dosage, Side Effects, Food Interaction and all others data.

An antibiotic similar to flucloxacillin used in resistant staphylococci infections.

Cloxasaph-250 is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Cloxasaph-250 has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Cloxasaph-250 results from the inhibition of cell wall synthesis and is mediated through Cloxasaph-250 binding to penicillin binding proteins (PBPs). Cloxasaph-250 is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Cloxasaph-250
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Cloxasaph-250
Availability	Prescription only
Generic	Oxacillin
Oxacillin Other Names	Ossacillina, Oxacilina, Oxacillin, Oxacilline, Oxacillinum, Oxazocillin, Oxazocilline
Related Drugs	amoxicillin, prednisone, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin
Type	Bottle
Formula	C₁₉H₁₉N₃O₅S
Weight	Average: 401.436 Monoisotopic: 401.104541423
Protein binding	94.2 +/- 2.1% (binds to serum protein, mainly albumin)
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Sapphire lifesciences
Available Country	Philippines
Last Updated:	September 19, 2023 at 7:00 am

Uses

Cloxasaph-250 is a penicillin antibiotic used to treat a number of susceptible bacterial infections.

Used in the treatment of resistant staphylococci infections.

Cloxasaph-250 is also used to associated treatment for these conditions: Catheter Related Infections, Community Acquired Pneumonia (CAP), Infections caused by penicillinase-producing staphylococci, Necrotizing Soft Tissue Infections, Surgical Site Infections

How Cloxasaph-250 works

By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Cloxasaph-250 inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Cloxasaph-250 interferes with an autolysin inhibitor.

Food Interaction

No interactions found.

[Moderate] ADJUST DOSING INTERVAL: Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.

The therapeutic effect of the antimicrobial may be reduced.

MANAGEMENT: The interacting penicillin should be administered one hour before or two hours after meals.

Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.

Cloxasaph-250 Hypertension interaction

[Moderate] Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.

Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg<5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.

The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.

In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.

Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.